These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 7546886)

  • 1. [Cancers of the breast. First line chemotherapy for cancers of the breast].
    Mauriac L
    Bull Cancer Radiother; 1995; 82(2):158-67. PubMed ID: 7546886
    [No Abstract]   [Full Text] [Related]  

  • 2. [Principles of adjuvant drug therapy in breast cancer].
    Castiglione M; Schnürch HG; Bender HG; Goldhirsch A
    Gynakologe; 1994 Apr; 27(2):49-63. PubMed ID: 8039743
    [No Abstract]   [Full Text] [Related]  

  • 3. [Neoadjuvant chemotherapy of patients with breast carcinoma].
    Jakesz R; Taucher S; Gnant M; Gebhard B; Kandioler D; Rudas M; Djavanmard M; Steger G
    Zentralbl Chir; 1998; 123 Suppl 5():147-50. PubMed ID: 10063601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant treatment of breast cancer.
    Akerley WL
    R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.
    Lohrisch C; Paltiel C; Gelmon K; Speers C; Taylor S; Barnett J; Olivotto IA
    J Clin Oncol; 2006 Oct; 24(30):4888-94. PubMed ID: 17015884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does neoadjuvant/adjuvant chemotherapy change the natural history of classic invasive lobular carcinoma?
    Katz A
    J Clin Oncol; 2005 Sep; 23(27):6796; author reply 6796-7. PubMed ID: 16170189
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant systemic therapy of breast carcinoma].
    Wickramanayake PD; Katay I; Josting A; Diehl V
    Med Klin (Munich); 1996 Oct; 91(10):646-53. PubMed ID: 9019642
    [No Abstract]   [Full Text] [Related]  

  • 10. [Some prognostic factors in the combined therapy of locally advanced breast cancer].
    Voznyĭ EK; Kharchenko VP; Gurov SN; Dobrovol'skaia NIu; Bol'shakova SA
    Vopr Onkol; 2000; 46(6):732-6. PubMed ID: 11219949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy for breast cancer: we are solving the puzzle, but pieces are still missing.
    Pritchard KI
    J Natl Cancer Inst; 2007 Apr; 99(7):494-5. PubMed ID: 17405988
    [No Abstract]   [Full Text] [Related]  

  • 13. Patterns of care: how American oncologists are treating stage II breast cancer.
    Oncology (Williston Park); 1987 Mar; 1(1):54, 56. PubMed ID: 3275333
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical margin and breast recurrence after breast-conserving therapy.
    Horiguchi J; Iino Y; Takei H; Maemura M; Yokoe T; Niibe H; Yamakawa M; Nakajima T; Oyama T; Morishita Y
    Oncol Rep; 1999; 6(1):135-8. PubMed ID: 9864416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effectiveness of adjuvant systemic therapy in organ-preserving therapy of breast cancer].
    Semiglazov VF; Kanaev SV; Bugrova IL; Chagunava OL
    Vopr Onkol; 1998; 44(4):408-13. PubMed ID: 9807203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
    Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determining factors for adjuvant treatment of breast cancer in the Côte d'Or region 1982-1990. Registry of gynecologic cancers at the Côte d'Or].
    Coudert B; Chaplain G; Milan C; Janoray P
    Bull Cancer; 1996 Jan; 83(1):54-62. PubMed ID: 8672857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
    Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
    J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy.
    Bijker N; Rutgers EJ; Peterse JL; van Dongen JA; Hart AA; Borger JH; Kroon BB
    Cancer; 1999 Apr; 85(8):1773-81. PubMed ID: 10223572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.